Combination therapy of an inhibitor of group VIA phospholipase A 2 with paclitaxel is highly effective in blocking ovarian cancer development

Hui Li, Zhenwen Zhao, Caryl Antalis, Zhanzhong Zhao, Robert Emerson, Gang Wei, Sheng Zhang, Zhong-Yin Zhang, Yan Xu

Research output: Contribution to journalArticle

15 Citations (Scopus)

Abstract

We and others have shown that calcium-independent phospholipase A 2 (iPLA2) is involved in epithelial ovarian cancer (EOC). Hence, we propose that iPLA2 is a potential effective and novel target for EOC. We tested this concept and found that bromoenol lactone (BEL), a selective inhibitor of iPLA2, significantly inhibited EOC metastatic tumor growth in mouse xenograft models using human SKOV3 and HEY ovarian cancer cells. Moreover, the combination of BEL with paclitaxel (PTX), one of the most commonly used therapeutic agents in EOC, almost completely blocked tumor development in the xenograft mouse model. BEL showed no detectable cytotoxic effects in mice. Another iPLA2 inhibitor, FKGK11, also inhibited tumor development in the xenograft mouse model, supporting that the major target of action was iPLA2. The additional effects of BEL with PTX in vivo likely stem from their distinct cellular effects. BEL and FKGK11 reduced adhesion, migration, and invasion of EOC cells in vitro; the reduced ability to adhere, migrate, and invade seems to increase the vulnerability of tumor cells to PTX. These results provide an important basis for the development of new treatment modalities for EOC.

Original languageEnglish
Pages (from-to)452-461
Number of pages10
JournalAmerican Journal of Pathology
Volume179
Issue number1
DOIs
StatePublished - Jul 2011

Fingerprint

Phospholipases A
Group Psychotherapy
Paclitaxel
Ovarian Neoplasms
Heterografts
Neoplasms
Aptitude
Ovarian epithelial cancer
6-(bromomethylene)tetrahydro-3-(1-naphthaleneyl)-2H-pyran-2-one
Calcium
Growth

ASJC Scopus subject areas

  • Pathology and Forensic Medicine

Cite this

Combination therapy of an inhibitor of group VIA phospholipase A 2 with paclitaxel is highly effective in blocking ovarian cancer development. / Li, Hui; Zhao, Zhenwen; Antalis, Caryl; Zhao, Zhanzhong; Emerson, Robert; Wei, Gang; Zhang, Sheng; Zhang, Zhong-Yin; Xu, Yan.

In: American Journal of Pathology, Vol. 179, No. 1, 07.2011, p. 452-461.

Research output: Contribution to journalArticle

@article{388c4610b6714d108b7d49e6e9833b8f,
title = "Combination therapy of an inhibitor of group VIA phospholipase A 2 with paclitaxel is highly effective in blocking ovarian cancer development",
abstract = "We and others have shown that calcium-independent phospholipase A 2 (iPLA2) is involved in epithelial ovarian cancer (EOC). Hence, we propose that iPLA2 is a potential effective and novel target for EOC. We tested this concept and found that bromoenol lactone (BEL), a selective inhibitor of iPLA2, significantly inhibited EOC metastatic tumor growth in mouse xenograft models using human SKOV3 and HEY ovarian cancer cells. Moreover, the combination of BEL with paclitaxel (PTX), one of the most commonly used therapeutic agents in EOC, almost completely blocked tumor development in the xenograft mouse model. BEL showed no detectable cytotoxic effects in mice. Another iPLA2 inhibitor, FKGK11, also inhibited tumor development in the xenograft mouse model, supporting that the major target of action was iPLA2. The additional effects of BEL with PTX in vivo likely stem from their distinct cellular effects. BEL and FKGK11 reduced adhesion, migration, and invasion of EOC cells in vitro; the reduced ability to adhere, migrate, and invade seems to increase the vulnerability of tumor cells to PTX. These results provide an important basis for the development of new treatment modalities for EOC.",
author = "Hui Li and Zhenwen Zhao and Caryl Antalis and Zhanzhong Zhao and Robert Emerson and Gang Wei and Sheng Zhang and Zhong-Yin Zhang and Yan Xu",
year = "2011",
month = "7",
doi = "10.1016/j.ajpath.2011.03.027",
language = "English",
volume = "179",
pages = "452--461",
journal = "American Journal of Pathology",
issn = "0002-9440",
publisher = "Elsevier Inc.",
number = "1",

}

TY - JOUR

T1 - Combination therapy of an inhibitor of group VIA phospholipase A 2 with paclitaxel is highly effective in blocking ovarian cancer development

AU - Li, Hui

AU - Zhao, Zhenwen

AU - Antalis, Caryl

AU - Zhao, Zhanzhong

AU - Emerson, Robert

AU - Wei, Gang

AU - Zhang, Sheng

AU - Zhang, Zhong-Yin

AU - Xu, Yan

PY - 2011/7

Y1 - 2011/7

N2 - We and others have shown that calcium-independent phospholipase A 2 (iPLA2) is involved in epithelial ovarian cancer (EOC). Hence, we propose that iPLA2 is a potential effective and novel target for EOC. We tested this concept and found that bromoenol lactone (BEL), a selective inhibitor of iPLA2, significantly inhibited EOC metastatic tumor growth in mouse xenograft models using human SKOV3 and HEY ovarian cancer cells. Moreover, the combination of BEL with paclitaxel (PTX), one of the most commonly used therapeutic agents in EOC, almost completely blocked tumor development in the xenograft mouse model. BEL showed no detectable cytotoxic effects in mice. Another iPLA2 inhibitor, FKGK11, also inhibited tumor development in the xenograft mouse model, supporting that the major target of action was iPLA2. The additional effects of BEL with PTX in vivo likely stem from their distinct cellular effects. BEL and FKGK11 reduced adhesion, migration, and invasion of EOC cells in vitro; the reduced ability to adhere, migrate, and invade seems to increase the vulnerability of tumor cells to PTX. These results provide an important basis for the development of new treatment modalities for EOC.

AB - We and others have shown that calcium-independent phospholipase A 2 (iPLA2) is involved in epithelial ovarian cancer (EOC). Hence, we propose that iPLA2 is a potential effective and novel target for EOC. We tested this concept and found that bromoenol lactone (BEL), a selective inhibitor of iPLA2, significantly inhibited EOC metastatic tumor growth in mouse xenograft models using human SKOV3 and HEY ovarian cancer cells. Moreover, the combination of BEL with paclitaxel (PTX), one of the most commonly used therapeutic agents in EOC, almost completely blocked tumor development in the xenograft mouse model. BEL showed no detectable cytotoxic effects in mice. Another iPLA2 inhibitor, FKGK11, also inhibited tumor development in the xenograft mouse model, supporting that the major target of action was iPLA2. The additional effects of BEL with PTX in vivo likely stem from their distinct cellular effects. BEL and FKGK11 reduced adhesion, migration, and invasion of EOC cells in vitro; the reduced ability to adhere, migrate, and invade seems to increase the vulnerability of tumor cells to PTX. These results provide an important basis for the development of new treatment modalities for EOC.

UR - http://www.scopus.com/inward/record.url?scp=80052464802&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=80052464802&partnerID=8YFLogxK

U2 - 10.1016/j.ajpath.2011.03.027

DO - 10.1016/j.ajpath.2011.03.027

M3 - Article

C2 - 21703423

AN - SCOPUS:80052464802

VL - 179

SP - 452

EP - 461

JO - American Journal of Pathology

JF - American Journal of Pathology

SN - 0002-9440

IS - 1

ER -